Free Trial
NYSE:NVO

Novo Nordisk A/S (NVO) Stock Price, News & Analysis

$136.02
+0.45 (+0.33%)
(As of 05/24/2024 ET)
Today's Range
$134.22
$136.68
50-Day Range
$122.70
$136.02
52-Week Range
$75.56
$138.28
Volume
2.84 million shs
Average Volume
4.65 million shs
Market Capitalization
$610.39 billion
P/E Ratio
46.90
Dividend Yield
0.98%
Price Target
$133.60

Novo Nordisk A/S MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
1.8% Downside
$133.60 Price Target
Short Interest
Healthy
0.08% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.81mentions of Novo Nordisk A/S in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
26.53%
From $3.43 to $4.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.77 out of 5 stars

Medical Sector

627th out of 917 stocks

Pharmaceutical Preparations Industry

288th out of 417 stocks

NVO stock logo

About Novo Nordisk A/S Stock (NYSE:NVO)

Novo Nordisk A/S is a global healthcare company specializing in the research, development, production, and marketing of pharmaceutical products to treat diabetes, obesity, and other chronic diseases. The company was founded in 1923 in Denmark and is headquartered in Bagsværd, Denmark.

Novo Nordisk has operations in more than 80 countries, including production facilities in nine countries, and employs approximately 48,500 people worldwide.

Novo Nordisk's mission is to discover and develop innovative medicines to help people with chronic diseases lead longer, healthier lives. The company's key therapeutic areas include diabetes, obesity, hemophilia, growth hormone therapy, and other severe chronic diseases. Novo Nordisk is the world's largest producer of insulin and has been at the forefront of diabetes care for more than 95 years.

Lars Fruergaard Jørgensen is the President and CEO of Novo Nordisk A/S, a position he has held since 2017. Jørgensen joined Novo Nordisk in 1991 and has held various management positions, including Executive Vice President and Head of Corporate Development, Strategy and Biopharmaceuticals.

Novo Nordisk has consistently delivered strong financial performance over the past few years. Novo Nordisk's profit margin has remained consistently high, with a net margin of approximately 30%. In terms of debt, Novo Nordisk has maintained a conservative approach. Novo Nordisk's debt has kept pace with its assets for several years. The company's cash reserves have not always been healthy, but in 2022 Novo Nordisk made a profit for the first time since 2018.

Novo Nordisk's valuation metrics compare favorably to industry peers. It has a price-to-earnings ratio in line with its peers but a price-to-book ratio significantly higher than the industry average. Novo Nordisk's high P/B ratio reflects its strong brand, market position, and financial performance.

Novo Nordisk's stock has performed well over the past few years, with a 3-year annualized return of around 23%. The stock price has shown some volatility, with significant price movements in response to regulatory and market news related to diabetes and obesity markets. 

Novo Nordisk operates in the highly competitive and rapidly evolving pharmaceutical industry, specifically in diabetes and obesity markets. The global diabetes market is expected to grow at a CAGR of 5.7% from 2022 to 2027, driven by the increasing prevalence of diabetes, especially in emerging markets, and the growing demand for innovative diabetes treatments. In the obesity market, the global prevalence of obesity has been steadily increasing, and it is expected to continue to rise, driving demand for effective obesity treatments.

Novo Nordisk faces intense competition from several large and small pharmaceutical companies in the diabetes and obesity markets. The company's main competitors in the diabetes market include Sanofi, Eli Lilly, and AstraZeneca, while its main competitors in the obesity market include Roche, Novartis, and Eisai.

The company's competitive position is based on factors such as the quality and effectiveness of its products, its research and development capabilities, its brand reputation, and ability to adapt to changing market dynamics.

Novo Nordisk is also subject to various regulatory and political issues that can impact its operations and financial performance. The company must comply with strict regulatory requirements in each country it operates, including the US FDA and the European Medicines Agency. Changes in regulatory requirements, such as changes to reimbursement policies, can significantly impact the company's financial performance.

Novo Nordisk has several growth opportunities to pursue in the coming years. The company is investing heavily in research and development to develop new and innovative treatments for diabetes and obesity, as well as other chronic diseases. Novo Nordisk has a strong pipeline of potential products in development, including GLP-1 receptor agonists, which have shown promise in clinical trials for treating obesity.

The company also expands in emerging markets, such as China and India, with significant and growing demand for diabetes and obesity treatments. Novo Nordisk has established partnerships with local companies in these markets to help drive growth and increase product access.

Novo Nordisk has pursued acquisitions and partnerships to expand its product offerings and capabilities. In 2021, the company acquired Prothena's ATTR amyloidosis program, a potential treatment for a rare and debilitating disease. This acquisition will strengthen Novo Nordisk's position in the rare disease market.

Novo Nordisk faces several risks and challenges that could impact its operations and financial performance. The company's success is heavily dependent on the success of its products in the diabetes and obesity markets, and any setbacks in clinical trials or product launches could significantly impact its financial performance.

In addition, Novo Nordisk faces regulatory and political risks, as changes in regulations or policies could impact its ability to operate or sell its products in specific markets. The company is also subject to intellectual property risks, as competitors may seek to challenge its patents and market their products.

Novo Nordisk also faces risks related to supply chain disruptions and production delays, as well as cybersecurity and data privacy risks.

NVO Stock Price History

NVO Stock News Headlines

Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon (NVO)
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs
MarketBeat Week in Review – 4/22 - 4/26
Investors continue to look for clarity as tech earnings sent stocks higher to end the week, even as investors hope for rate cuts fade as inflation rises
MarketBeat Week in Review – 4/22 - 4/26 (NVO)
Investors continue to look for clarity as tech earnings sent stocks higher to end the week, even as investors hope for rate cuts fade as inflation rises
Novo Nordisk A/S - share repurchase programme
See More Headlines
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 4/2 Dividend
3/22/2024
Dividend Payable
4/02/2024
Last Earnings
5/02/2024
Today
5/24/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
63,370
Year Founded
1923

Price Target and Rating

Average Stock Price Target
$133.60
High Stock Price Target
$163.00
Low Stock Price Target
$110.00
Potential Upside/Downside
-1.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$12.15 billion
Pretax Margin
45.82%

Debt

Sales & Book Value

Annual Sales
$33.71 billion
Cash Flow
$3.06 per share
Book Value
$3.21 per share

Miscellaneous

Outstanding Shares
4,487,530,000
Free Float
4,484,391,000
Market Cap
$610.39 billion
Optionable
Optionable
Beta
0.43

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


NVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Novo Nordisk A/S stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVO shares.
View NVO analyst ratings
or view top-rated stocks.

What is Novo Nordisk A/S's stock price target for 2024?

8 equities research analysts have issued 1-year target prices for Novo Nordisk A/S's stock. Their NVO share price targets range from $110.00 to $163.00. On average, they predict the company's share price to reach $133.60 in the next twelve months. This suggests that the stock has a possible downside of 1.8%.
View analysts price targets for NVO
or view top-rated stocks among Wall Street analysts.

How have NVO shares performed in 2024?

Novo Nordisk A/S's stock was trading at $103.45 at the start of the year. Since then, NVO stock has increased by 31.5% and is now trading at $136.02.
View the best growth stocks for 2024 here
.

When is Novo Nordisk A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our NVO earnings forecast
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) released its earnings results on Thursday, May, 2nd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.06. The company had revenue of $9.52 billion for the quarter, compared to analysts' expectations of $9.23 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 91.70% and a net margin of 36.56%.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a Semi-Annual dividend on Wednesday, January 31st. Investors of record on Monday, March 25th will be given a dividend of $0.664 per share on Tuesday, April 2nd. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, March 22nd. This is a positive change from the stock's previous Semi-Annual dividend of $0.22.
Read our dividend analysis for NVO
.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $1.33 per share and currently has a dividend yield of 0.99%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 45.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 30.65% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

When did Novo Nordisk A/S's stock split?

Novo Nordisk A/S's stock split before market open on Wednesday, September 20th 2023. The 2-1 split was announced on Wednesday, September 20th 2023. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $40.3 billion-$43.0 billion, compared to the consensus revenue estimate of $41.3 billion.

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.47%), Fayez Sarofim & Co (0.26%), Folketrygdfondet (0.20%), Price T Rowe Associates Inc. MD (0.19%), Capital International Investors (0.16%) and Everett Harris & Co. CA (0.14%).
View institutional ownership trends
.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Novo Nordisk A/S have any subsidiaries?
The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., CS Solar Fund XIV LLC, Calibrium, Corvidia Therapeutics, Corvidia Therapeutics Inc., Dicerna Pharmaceuticals, Dicerna Pharmaceuticals Inc., Emisphere Technologies, Emisphere Technologies Inc., MB2 LLC, NNE A/S, Neotope Neuroscience Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk (Shanghai) Pharma Trading Co. Ltd., Novo Nordisk B.V., Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comércio Produtos Farmacêuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Finance (Netherlands) B.V., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungária Kft., Novo Nordisk Inc., Novo Nordisk India Holding Pte Ltd., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk North America Operations A/S, Novo Nordisk Norway AS, Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZE, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma Sp.z.o.o., Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals A/S, Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Pharmatech US Inc., Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region China A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Saudi for Trading, Novo Nordisk Scandinavia AB, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representación C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, Ziylo, and Ziylo Limited.
Read More
This page (NYSE:NVO) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners